July 12, 2018 – Global executive search firm Coulter Partners has placed Emilie Viey as the new CEO of Ovizio Imaging Systems, a life science imaging technology company. Philip Mathuis, who co-founded Ovizio, recently stepped down. Philipp Buis, Coulter’s executive director, led the assignment. Dr. Viey will lead Ovizio’s further development as solution provider for imaging applications in life sciences.
“We are delighted to welcome Emilie to Ovizio, and I thank the exceptional team at Coulter Partners for their work in achieving this high-caliber appointment,” said Philippe Vercruyssen, executive chairman of Ovizio. “Emilie brings deep scientific knowledge, understanding and experience in cell based instrumentation, in addition to marketing and sales expertise.”
Dr. Viey joins Ovizio from ACEA Biosciences, a cell analysis instruments company based in San Diego, where she was director of commercialization and set up the complete organization for Europe. Before that, she was application scientist at Roche Diagnostics France for Cellular Analysis Instruments (Cell Counters, Imaging Platform and Label Free Cell Analyzers).
|Check out our latest upload from Norman Broadbent|
“Ovizio has a unique technology platform and product portfolio for automated label-free imaging of cells that offer the capability to fingerprint cells for a large number of applications,” said Dr. Viey. “I am convinced of the tremendous value Ovizio can bring to both traditional cellular bioprocessing and the most advanced cell therapy processes. I very much look forward to working with Ovizio’s team to further expand the company’s reach.”
Ovizio is an innovative Belgian company developing efficient quantitative microscopy solutions for life sciences applications. The company’s microscopes offer easy-to-use, label-free and non-invasive tools for real-time 3D and 4D imaging of living cells.
Life Sciences Specialists
Coulter Partners is a senior-level executive search boutique focused exclusively on identifying global life sciences leaders and board directors. The firm serves clients in the pharmaceuticals, biotechnology, medical devices, diagnostics, CRO and services sectors.
Tapping Outside Talent for Life Science and Healthcare
For these top 50 executive recruiters working in the life science and healthcare sectors, the last decade has been one of transformation. Pressure on pricing, regulatory changes, emerging innovations, growth, and an uncertain political environment have all helped shape a new field of play.
|Top 50 Ranking|
Coulter currently operates overseas offices in the U.K., Germany, Switzerland and Denmark. In the U.S., the firm has offices in Cambridge, MA; Princeton, NJ; Pittsburgh; Los Angeles; and Short Hills, NJ.
Mr. Buis focuses on senior-level international search across a broad spectrum of scientific, commercial and business functions in the pharmaceuticals, med tech and biotech sectors with an emphasis on discovery, global clinical development and medical affairs. He heads Coulter Partners’ Zurich office, having joined the firm last year. Mr. Buis draws on an extensive track record gained over 18 years in executive search, partnering with leading niche players as well as large cap corporations within life sciences.
Persistent talent shortages and the need to develop and retain employees with critical business and technology skill-sets will continue to challenge global life sciences companies for the foreseeable future, according to Deloitte’s global sector outlook on life sciences. Navigating this new world of work requires a dramatic change in strategies for leadership, talent and human resources. What’s more, the global life sciences sector in the midst of a turbulent transformation, making the need for innovative leaders more important than ever.
“Our sector has changed beyond anyone’s expectations over the last two decades,” said Bianca Coulter, CEO of Coulter Partners. “We need to understand the appetites and needs of the major multinationals. This requires reach into all corners of the market. While our office network is growing, the key has been to have multilingual, multi-market experienced and connected researchers and consultants. Our team speaks many languages and has worked in all major bio-pharma markets and is organized as one P&L, to ensure collaborative information and experience sharing.”
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; Stephen Sawicki, Managing Editor; and Andrew W. Mitchell, Managing Editor – Hunt Scanlon Media